Projects

Pertaprime: An investigator-driven phase II-III randomised, observer-blind, controlled trial to demonstrate non-inferior immunogenicity of Pertagen® in comparison to Boostrix® in healthy young Australian adults aged 18-25 years

Pertaprime is a study designed to learn more about a new vaccine, called Pertagen®, to protect young adults against pertussis “whooping cough”.

BCG vaccination to Reduce the impact of COVID-19 in Australian healthcare workers following Coronavirus Exposure (BRACE) Trial

This trial will determine whether BCG vaccination reduces the incidence and severity of COVID-19 but also whether BCG vaccination reduces other respiratory illnesses in healthcare workers.

ATOMIC Ears: A Phase IIB randomised controlled trial to assess safety, tolerability and acceptability of a 5-day Dornase alfa treatment as an adjunct therapy to ventilation tube insertion for otitis media in children

Chris Jennifer Lea-Ann Peter Ruth Brennan-Jones Kent Kirkham Richmond Thornton PhD RN PhD MBBS MRCP(UK) FRACP PhD Head, Ear and Hearing Health Clinical Research Manager Co-Head, Bacterial Respiratory Infectious Disease Group; Microbiology Lead,

A randomized, controlled, observer-blind, phase 1/2a study to evaluate the safety, reactogenicity, and immunogenicity of Ad26.RSV.preF in RSV-seronegative toddlers 12 to 24 months of age

This study aims to investigate a new vaccine which has been developed to protect children from RSV.

A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 in healthy infants (PNEU-PED-EU-1)

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical Research Manager Head, Vaccine Trials Group Jennifer completed her Diploma of Nursing in 1986 at Fremantle